A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa [Extension Study] (NCT06799000)
CLOU064J12303B
This trial is Currently recruiting
Registration number NCT06799000
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Prof Johannes S Kern
Key inclusion data
Rollover study from CLOU064J12301 (AH_238/24) – NOT RECRUITING NEW PARTICIPANTSMore information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.